As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com. Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

Learn more at marylandoncology.com. Dr. Sastry is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Iron Deficiency Anemia, and Childhood Iron Deficiency Anemia.

Edward Lee, M.D. was named one of Baltimore’s “Top Doc’s” by Baltimore Magazine in 2000 and 2002. After receiving additional training in Hematology and Medical Oncology at the University of Maryland in 1984, he remained on faculty until 1997. During his academic career, Dr. Lee was chairman of the training program for five years, started the Bone Marrow Transplant Program at the University of Maryland in 1993, and wrote 50 original articles on leukemia, lymphoma and related diseases. In 1997, Dr. Lee entered private practice as Chief of Hematology and Medical Oncology at Sinai Hospital. Practicing in Columbia since 2001, Dr. Lee treats patients with all forms of cancer, maintaining a particular interest in breast cancer, leukemia, and lymphomas. Learn more at marylandoncology.com. Dr. Lee is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Polycythemia Vera, Paget Disease of the Breast, Breast Cancer, and Primary Lymphoma of the Brain.

Andrew Mener, M.D. has experience treating a wide range of adult hematologic and oncologic disorders, with a particular interest in treating breast, lung, gastrointestinal and hematologic malignancies. He takes great pride in delivering personalized, compassionate care and strives to effectively explain complex treatment options to his patients. He strongly believes in the importance of treating each and every patient as an individual. Learn more at marylandoncology.com. Dr. Mener is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Iron Deficiency Anemia, and Severe Congenital Neutropenia.

Najeff Waseem is a Hematologist and a Hematologist Oncology provider in Columbia, Maryland. Dr. Waseem has been practicing medicine for over 10 years and is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Thrombocytopenia, Agranulocytosis, Chronic Familial Neutropenia, and Triple-Negative Breast Cancer.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Jin He, M.D., Ph.D., is a professor of surgery at the Johns Hopkins University School of Medicine and is the Division Chief of Hepato-Pancreato-Biliary & Gastrointestinal Surgical Oncology. Dr. He specializes in diseases and tumors of the pancreas, liver, bile duct, and gallbladder. He performs open as well as minimally invasive (robotic and laparoscopic) surgery, including the Whipple procedure. Dr. He received his medical degree from Beijing Medical University and a Ph.D. in oncology from Fudan University Shanghai Medical College. He completed the Halsted general surgery residency training at Johns Hopkins, followed by an ACGME accredited fellowship in complex general surgical oncology at Johns Hopkins. Dr. He is the John Cameron Professor of Alimentary Tract Diseases. Dr. He’s research focuses on personalized treatment through stratifying pancreatic tumors on their genetic features. He holds several patents in anti-cancer vascular targeting agents and has published extensively in peer-reviewed journals and lectured internationally. He serves on several national committees, including the NCCN panel on neuroendocrine tumors and the Alliance for Clinical Trials in Oncology. Dr. He is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Cholangiocarcinoma (Bile Duct Cancer), Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Narang is an Assistant Professor in the Johns Hopkins Department of Radiation Oncology & Molecular Sciences. A former chief resident in the department, Dr. Narang now specializes in radiation treatment for gastrointestinal malignancies, including pancreatic cancer, colorectal cancer, hepatobiliary malignancies, and gastric cancer. Dr. Narang has an interest in expanding multi-disciplinary care for patients with gastrointestinal malignancies. Make A Gift. Dr. Narang is rated as a Distinguished provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Pancreatoblastoma, Pancreaticoduodenectomy, and Pancreatectomy.

Stuart Selonick is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Selonick is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Idiopathic Neutropenia, and Lung Cancer. Dr. Selonick is currently accepting new patients.

Peter Graze is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Graze is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Graze is currently accepting new patients.

Jeanine Werner is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Werner is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Familial Colorectal Cancer, and Virilizing Ovarian Tumor. Dr. Werner is currently accepting new patients.

David Weng is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Weng is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Weng is currently accepting new patients.

Jason Taksey is an Oncologist and a Hematologist in Columbia, Maryland. Dr. Taksey is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Urothelial Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and WT1-Related Wilms Tumor Syndromes. Dr. Taksey is currently accepting new patients.

Jose Mendoza is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Mendoza is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Familial Colorectal Cancer. Dr. Mendoza is currently accepting new patients.

Rita Gupta is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Gupta is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Iron Deficiency Anemia, Childhood Iron Deficiency Anemia, Paget Disease of the Breast, and Breast Cancer. Dr. Gupta is currently accepting new patients.

Nicholas Demonaco is a Hematologist Oncology specialist and a Hematologist in Columbia, Maryland. Dr. Demonaco is rated as an Experienced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pulmonary Embolism, Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, and Anemia. Dr. Demonaco is currently accepting new patients.

Ana De Jesus is an Oncologist in Baltimore, Maryland. Dr. De Jesus is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Pancreatic Cancer, Neuroendocrine Tumor, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dr. Cameron has had a long and distinguished career in alimentary tract diseases and specifically in pancreatic cancer. He has won worldwide acclaim for mastering the Whipple procedure. At the beginning of his career, the mortality rate from the Whipple procedure was nearly 30 percent. He has worked to lower that to 1 percent to 2 percent at Johns Hopkins. He has operated on more patients with pancreatic cancer and done more Whipple resections than any other surgeon in the world. In addition to maintaining a busy practice that focuses mainly on pancreatic surgery, he has been a leader in the surgical profession, serving as president of the American College of Surgeons, Society for Surgery of the Alimentary Tract, Southern Surgical Association, Society of Clinical Surgery, Society of Surgical Chairmen, Halsted Society and American Surgical Association. He served as chief of surgery for The Johns Hopkins Hospital for nineteen years. Dr. Cameron obtained his undergraduate degree from Harvard University in 1958, and his medical degree from The Johns Hopkins University School of Medicine in 1962. All of his training in General and Thoracic Surgery was obtained at The Johns Hopkins Hospital. Dr. Cameron is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pancreatic Islet Cell Tumor, Pancreaticoduodenectomy, and Pancreatectomy.

Dung Le, M.D. is a professor of oncology at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center. Her research interests include novel approaches to patients with gastrointestinal malignancies. She has served as the principal investigator (PI) on many clinical trials focused on testing immunotherapy in patients with gastrointestinal malignancies and she has also served as the national PI on several studies including: anti-programmed death-1 (PD-1) in tumors with mismatch repair deficiency; a clinical trial in advanced pancreatic cancer patients evaluating the safety, tolerability and immune response to CRS-207, a listeria vaccine platform which has been modified to express the tumor antigen mesothelin; a multi-center, phase 2 study testing CRS-207 as a boost to allogenic pancreatic tumor cells transfected with GM-CSF gene (GVAX) for treatment of advanced pancreatic adenocarcinoma (PDA); a trial testing GVAX/ipilimumab in the maintenance setting for metastatic pancreatic cancer; and GVAX/CRS-207 +/- nivolumab in metastatic pancreatic cancer. These studies incorporate extensive laboratory correlates and have involved collaborations with clinicians and bench scientists with expertise in the fields of immunotherapy and cancer genomics. Dr. Le is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. Her top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Gastroesophageal Junction Cancer, and Familial Pancreatic Cancer.

Richard Burkhart, M.D., is an Associate Professor of Surgery at The Johns Hopkins Hospital with a focus on complex minimally-invasive surgery and research for cancers of the pancreas, liver and bile ducts. Dr. Burkhart received his medical degree from Boston University and completed his surgical residency and research fellowships at the Thomas Jefferson University Hospital in Philadelphia and the Cold Spring Harbor Laboratories. He is a member of several professional organizations, including the American Association of Cancer Research, the American College of Surgeons, the Society of Surgery for the Alimentary Tract, the Pancreas Club, and the Society of Surgical Oncology. Outside the operating room, Dr. Burkhart heads a multidisciplinary laboratory team dedicated to bringing next-generation precision medicine approaches into the routine clinical care of patients that we serve. He has a particular research interest in using personalized models of pancreas cancer, made from tumor during and immediately after surgical resection, to select the best chemotherapy for each patient to support long-term survival and improve rates of disease cure. The laboratory team, funded in part by the National Institutes of Health, the National Cancer Institute, the Lustgarten Foundation and Stand Up to Cancer, is also thankful to the many patients who have supported the work through philanthropic gift. Dr. Burkhart is rated as an Advanced provider by MediFind in the treatment of Pancreatoblastoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy.